- Conditions
- Pain
- Interventions
- a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 2,633
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Volunteers
- Interventions
- TAK-954, TAK-954 Placebo
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Cancer, Lung, Metastasis
- Interventions
- Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lupus Nephritis
- Interventions
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Pterygium
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Healthy Volunteers
- Interventions
- TS-161, TS-161 Placebo
- Drug
- Lead sponsor
- Taisho Pharmaceutical R&D Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Healthy Subject
- Interventions
- Broccoli Sprout Extract (BSE)
- Drug
- Lead sponsor
- Julie E. Bauman, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Fallopian Tube Cancer, Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Uterine Sarcoma, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Uterine Sarcoma, Stage IV Vulvar Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer
- Interventions
- stereotactic radiosurgery, quality-of-life assessment
- Radiation · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Liver Transplant Rejection
- Interventions
- CFZ533, Tacrolimus - MMF - corticosteroids
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
- Interventions
- Sotagliflozin initiation
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment
- Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more
- Conditions
- Developmental Language Disorder, Language Impairment
- Interventions
- Sentence recast
- Behavioral
- Lead sponsor
- University of Houston
- Other
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Allergy
- Interventions
- Oral Food Challenge (OFC): Peanut Protein
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 7 more
- Conditions
- Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
- Interventions
- Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Up to 3 Days
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- 18F-DCFPyL
- Drug
- Lead sponsor
- Ashok Muthukrishnan
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Scar, Cesarean Section; Dehiscence
- Interventions
- Scar Deactivation Surface Release Technique protocol, Scar Infiltration with 0.25-1% Lidocaine, Physical therapy
- Other
- Lead sponsor
- Jennifer Loomis
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Scott Air Force Base, Illinois
- Conditions
- Asthma
- Interventions
- fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
- Conditions
- Liver Transplantation
- Interventions
- Everolimus + reduced tacrolimus, Standard tacrolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Baltimore, Maryland + 6 more
- Conditions
- Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders (Including Diabetes Mellitus)
- Interventions
- Diazoxide, Placebo
- Drug
- Lead sponsor
- Meredith Hawkins
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Interventions
- IV Ganciclovir, Placebo
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 14
- States / cities
- Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
- Conditions
- Prostatic Hyperplasia
- Interventions
- FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- dulaglutide, Warfarin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Other Conditions That May Be A Focus of Clinical Attention
- Interventions
- Adefovir dipivoxil
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California